Over the past 12 months, 1 insider at Aclaris Therapeutics, Inc. filed 1 open-market SEC Form 4 transaction on ACRS: 0 purchases worth $0 and 1 sale worth $1.4M. Insiders have been net sellers over this period. The most recent filing was on Apr 23, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 23, 26 | Braden Michael Leonard | SELL | 300.0K | $4.53 | $1.4M |
| Nov 19, 24 | Anand MehraDirector | BUY | 666.7K | $2.25 | $1.5M |
| Aug 5, 24 | Braden Michael LeonardTenPercentOwner | BUY | 206.0K | $1.24 | $255K |
| Aug 2, 24 | Braden Michael LeonardTenPercentOwner | BUY | 167.5K | $1.29 | $216K |
| Jul 31, 24 | Braden Michael LeonardTenPercentOwner | BUY | 100.0K | $1.33 | $133K |
| Jul 30, 24 | Braden Michael LeonardTenPercentOwner | BUY | 173.7K | $1.30 | $226K |
| Jul 22, 24 | Braden Michael LeonardTenPercentOwner | BUY | 17.7K | $1.33 | $24K |
| Jul 19, 24 | Braden Michael LeonardTenPercentOwner | BUY | 6.7K | $1.30 | $9K |
| Jul 18, 24 | Braden Michael LeonardTenPercentOwner | BUY | 130.3K | $1.30 | $169K |
| Jul 5, 24 | Braden Michael LeonardTenPercentOwner | BUY | 123.0K | $1.15 | $141K |
| Jul 3, 24 | Braden Michael LeonardTenPercentOwner | BUY | 143.3K | $1.16 | $166K |
| Jul 2, 24 | Braden Michael LeonardTenPercentOwner | BUY | 86.1K | $1.14 | $98K |
| Jul 1, 24 | Braden Michael LeonardTenPercentOwner | BUY | 107.4K | $1.14 | $122K |
| Jun 28, 24 | Braden Michael LeonardTenPercentOwner | BUY | 801.0K | $1.13 | $897K |
| Jun 27, 24 | Braden Michael LeonardTenPercentOwner | BUY | 235.0K | $1.15 | $270K |
| Jun 18, 24 | Braden Michael LeonardTenPercentOwner | BUY | 50.0K | $1.13 | $57K |
| Jun 17, 24 | Braden Michael LeonardTenPercentOwner | BUY | 150.0K | $1.13 | $170K |
| Jun 14, 24 | Braden Michael LeonardTenPercentOwner | BUY | 345.0K | $1.17 | $404K |
| Jun 13, 24 | Braden Michael LeonardTenPercentOwner | BUY | 500.0K | $1.15 | $575K |
| Jun 12, 24 | Braden Michael LeonardTenPercentOwner | BUY | 82.6K | $1.14 | $94K |
| Jun 11, 24 | Braden Michael LeonardTenPercentOwner | BUY | 1.00M | $1.08 | $1.1M |
| Mar 4, 24 | Powell Andrew Kenneth WilliamDirector | BUY | 6.0K | $1.25 | $8K |
| Mar 1, 24 | Powell Andrew Kenneth WilliamDirector | BUY | 8.5K | $1.23 | $10K |
| Oct 23, 23 | Joseph MonahanChief Scientific Officer | SELL | 6.0K | $5.08 | $30K |
| Sep 6, 23 | Kevin BalthaserChief Financial Officer | BUY | 9.5K | $7.90 | $75K |
| Aug 28, 23 | James LoeropChief Business Officer | BUY | 14.7K | $6.80 | $100K |
| Aug 21, 23 | Joseph MonahanChief Scientific Officer | SELL | 6.0K | $7.32 | $44K |
| Jun 20, 23 | Joseph MonahanChief Scientific Officer | SELL | 6.0K | $10.28 | $62K |
| Mar 17, 23 | Douglas J. ManionPres and CEO | BUY | 6.3K | $7.86 | $50K |
| Mar 9, 23 | Douglas J. ManionPres and CEO | BUY | 6.5K | $7.74 | $50K |
| Mar 3, 23 | Kevin BalthaserChief Financial Officer | SELL | 894 | $12.63 | $11K |
| Mar 3, 23 | Joseph MonahanChief Scientific Officer | SELL | 16.0K | $12.63 | $203K |
| Mar 3, 23 | Neal WalkerDirector | SELL | 30.2K | $12.63 | $382K |
| Mar 2, 23 | Kevin BalthaserChief Financial Officer | SELL | 1.0K | $12.29 | $12K |
| Mar 2, 23 | Joseph MonahanChief Scientific Officer | SELL | 14.8K | $12.37 | $183K |
| Mar 2, 23 | Neal WalkerDirector | SELL | 29.0K | $12.37 | $359K |
| Feb 15, 23 | Joseph MonahanChief Scientific Officer | SELL | 5.0K | $13.06 | $65K |
| Feb 8, 23 | James LoeropChief Business Officer | SELL | 4.3K | $13.89 | $59K |
| Feb 2, 23 | Neal WalkerDirector | SELL | 3.1K | $17.54 | $53K |
| Feb 1, 23 | Neal WalkerDirector | SELL | 25.0K | $16.75 | $419K |
| Jan 4, 23 | Neal WalkerDirector | SELL | 15.0K | $14.89 | $223K |
| Jan 3, 23 | Neal WalkerDirector | SELL | 23.4K | $16.16 | $355K |
| Dec 15, 22 | Joseph MonahanChief Scientific Officer | SELL | 5.0K | $15.88 | $79K |
| Nov 14, 22 | Andrew N SchiffDirector | SELL | 1.4K | $17.08 | $23K |
| Nov 11, 22 | Andrew N SchiffDirector | SELL | 41.2K | $17.06 | $702K |
| Nov 10, 22 | Andrew N SchiffDirector | SELL | 11.4K | $17.02 | $194K |
| Oct 26, 22 | Andrew N SchiffDirector | SELL | 14.5K | $17.01 | $247K |
| Oct 25, 22 | Andrew N SchiffDirector | SELL | 12.0K | $17.02 | $205K |
| Oct 24, 22 | Andrew N SchiffDirector | SELL | 14.6K | $17.01 | $249K |
| Oct 18, 22 | Andrew N SchiffDirector | SELL | 32.1K | $16.89 | $542K |
Over the past 12 months, insiders at Aclaris Therapeutics, Inc. filed 0 open-market purchases worth $0 and 1 sale worth $1.4M on ACRS, which makes them net sellers over the period. The most recent Form 4 was filed on Apr 23, 26.
The largest recent open-market ACRS insider purchase in our data was $1.5M by Anand Mehra, Director, filed on Nov 19, 24.
1 different insider at Aclaris Therapeutics, Inc. filed open-market SEC Form 4 transactions on ACRS over the last 12 months.
InsiderTape plots every ACRS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Aclaris Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →